2016YFC1303800/National Key R&D Program of China[Grants and Funding] - Search Results

Year	Number of Results
2019	2
2020	3
2021	4
2022	1
2025	0

1

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events.

Bai R, Chen N, Chen X, Li L, Song W, Li W, Zhao Y, Zhang Y, Han F, Lyu Z, Cui J. Bai R, et al. Cancer Biol Med. 2021 Jul 14;18(4):1118-33. doi: 10.20892/j.issn.2095-3941.2021.0052. Online ahead of print. Cancer Biol Med. 2021. PMID: 34259422 Free PMC article.

2

Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.

Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Wei XW, et al. Thorac Cancer. 2020 Jun;11(6):1512-1521. doi: 10.1111/1759-7714.13419. Epub 2020 Apr 14. Thorac Cancer. 2020. PMID: 32291971 Free PMC article.

The non-TKD mutation might also be used as a therapeutic target in ERBB2-directed target therapy. KEY POINTS: Significant findings of the study ERBB2 mutations were more abundant within a nontyrosine domain than those within the tyrosine domain. ...

The non-TKD mutation might also be used as a therapeutic target in ERBB2-directed target therapy. KEY POINTS: Significant findings of …

3

Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.

Song J, Tian J, Zhang L, Qu X, Qian W, Zheng B, Zhang L, Zhao J, Niu M, Zhou M, Cui L, Liu Y, Zhao M. Song J, et al. Eur Radiol. 2019 May;29(5):2388-2398. doi: 10.1007/s00330-018-5912-2. Epub 2019 Jan 14. Eur Radiol. 2019. PMID: 30643941 Free PMC article.

CONCLUSION: The study demonstrated that the PIM yielded significantly higher performance to identify individual stage III-IV LSCC patients who can potentially benefit most from first-line chemotherapy, and predict the risk of failure from chemotherapy for individual patients. …

CONCLUSION: The study demonstrated that the PIM yielded significantly higher performance to identify individual stage III-IV LSCC patients w …

4

Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation.

Gu FF, Wu JJ, Liu YY, Hu Y, Liang JY, Zhang K, Li M, Wang Y, Zhang YA, Liu L. Gu FF, et al. Cancer Immunol Immunother. 2020 May;69(5):779-788. doi: 10.1007/s00262-020-02510-1. Epub 2020 Feb 12. Cancer Immunol Immunother. 2020. PMID: 32052078 Free PMC article.

5

Automatic pulmonary ground-glass opacity nodules detection and classification based on 3D neural network.

Ma H, Guo H, Zhao M, Qi S, Li H, Tian Y, Li Z, Zhang G, Yao Y, Qian W. Ma H, et al. Med Phys. 2022 Apr;49(4):2555-2569. doi: 10.1002/mp.15501. Epub 2022 Feb 10. Med Phys. 2022. PMID: 35092608

6

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level.

Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, Yang J, Xie Z, Guo W, Li F, Wu Y, Zhou Q. Guo L, et al. BMC Cancer. 2019 Apr 23;19(1):369. doi: 10.1186/s12885-019-5555-y. BMC Cancer. 2019. PMID: 31014278 Free PMC article.

7

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.

Peng LX, Jie GL, Li AN, Liu SY, Sun H, Zheng MM, Zhou JY, Zhang JT, Zhang XC, Zhou Q, Zhong WZ, Yang JJ, Tu HY, Su J, Yan HH, Wu YL. Peng LX, et al. Exp Hematol Oncol. 2021 Nov 10;10(1):52. doi: 10.1186/s40164-021-00245-y. Exp Hematol Oncol. 2021. PMID: 34758872 Free PMC article.

8

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism.

Liu SY, Zhou JY, Li WF, Sun H, Zhang YC, Yan HH, Chen ZH, Chen CX, Ye JY, Yang JJ, Zhou Q, Zhang XC, Wu YL. Liu SY, et al. Clin Transl Med. 2020 Jan;10(1):337-345. doi: 10.1002/ctm2.12. Clin Transl Med. 2020. PMID: 32508032 Free PMC article.

9

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.

Zhou Z, Liu Z, Ou Q, Wu X, Wang X, Shao Y, Liu H, Yang Y. Zhou Z, et al. Cancer Biol Med. 2021 Mar 12;18(2):490-501. doi: 10.20892/j.issn.2095-3941.2020.0120. Online ahead of print. Cancer Biol Med. 2021. PMID: 33710807 Free PMC article.

10

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Chen X, Fang L, Zhu Y, Bao Z, Wang Q, Liu R, Sun W, Du H, Lin J, Yu B, Chen S, Zhou J, Zhou J. Chen X, et al. Cancer Immunol Immunother. 2021 Dec;70(12):3513-3524. doi: 10.1007/s00262-021-02943-2. Epub 2021 Apr 25. Cancer Immunol Immunother. 2021. PMID: 33899131 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year